TSRL, Inc. to Present at the 2015 AAPS Annual Meeting and Exposition

Ann Arbor, Michigan, Sept 15th, 2015: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, is presenting at the 2015 AAPS Annual Meeting and Exposition, October 25-29, at the Orange County Convention Center in Orlando Florida.

Dawn Reyna, Sr. Director of Laboratory Services, will be presenting on the "Pharmacokinetics of Potent HPMPA and HPMPC Tyrosinamide Prodrugs with Broad Spectrum Antiviral Activity" and Deanna Mudie, on behalf of the University of Michigan College of Pharmacy, will be presenting on the "Influence of Fluid Shear Rate on the Dissolution Rate of Poorly Soluble Drug Particles; Implications for In Vivo Predictive In Vitro Dissolution Methodologies and Mechanistic Computational Modeling".

Abstracts are available here:

Pharmacokinetics of Potent HPMPA and HPMPC Tyrosinamide Prodrugs with Broad Spectrum Antiviral Activity

Influence of Fluid Shear Rate on the Dissolution Rate of Poorly Soluble Drug Particles

About TSRL, Inc.

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734-663-4233 x236, elipka@tsrlinc.com.

 

TSRL, Inc. Presents at the Cutting Edge/Drug Discovery & Development in Michigan Symposium

Ann Arbor, Michigan, Sept 15th, 2015: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, has presented on various topics at the Cutting Edge/Drug Discovery & Development in Michigan Symposium September 9th and 10th.

Eric Simon, PhD presented on the "Development of an LC-MS Assay for Measurement of of Intracellular Concentrations of Cidofovir Prodrug USC-505 and its Metabolites". Shyamala Ganesan, PhD presented on "Improved Intracellular Concentrations of Cidofovir Diphosphate Using an Oral Prodrug Approach". Andrew Hertig, MBA, presented on "The Preclinical Accelerator: A New Model for Drug Development".

Presentations are available for viewing here:

LC-MS Method for Measuring Cidofovir Prodrugs Poster

Intracellular Conversion of Cidofovir Prodrugs Poster

Preclinical Accelerator Model for Drug Development Poster

About TSRL, Inc.

TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734-663-4233 x236, elipka@tsrlinc.com.